<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04328636</url>
  </required_header>
  <id_info>
    <org_study_id>NebMag-PPHN Study</org_study_id>
    <nct_id>NCT04328636</nct_id>
  </id_info>
  <brief_title>Nebulized MgSO4 in Persistent Pulmonary Hypertension of Newborn</brief_title>
  <acronym>NebMag</acronym>
  <official_title>Nebulized Magnesium Sulfate for Treatment of Persistent Pulmonary Hypertension of The Newborn</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sohag University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sohag University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this pilot randomized controlled blinded study is to evaluate the feasibility of
      using nebulized magnesium sulfate in the treatment of PPHN.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The effectiveness and safety of nebulized magnesium sulfate (using isotonic solution in a
      dose of 1024 mg/hour) is compared with intravenous magnesium sulfate (200 mg/kg over 30
      minutes, followed by 50 mg/kg/hour) in treating mechanically ventilated neonates with severe
      persistent pulmonary hypertension of the newborn.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Actual">February 1, 2020</completion_date>
  <primary_completion_date type="Actual">October 31, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Two groups of neonates with PPHN
NebMag group: receive nebulized magnesium sulfate and intravenous placebo.
IVMag group: receive intravenous magnesium sulfate and nebulized placebo.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>Each neonate was assigned a unique identification number. Pharmacy filled the active and placebo preparations in similar containers with sealed code for identification. Participants' families, treating clinicians, nurses, echocardiographers, and data collectors were unaware of group assignment and drug/placebo therapy.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Oxygenation index (OI)</measure>
    <time_frame>At baseline to 2, 6, 12, and 24 hours following study drug administration.</time_frame>
    <description>Change in oxygenation index (OI) calculated by the classic formula:
OI = [(FiO2 * MAP) / PaO2]
FiO2 expressed in %; MAP in cmH2O/mmHg; and PaO2 in mmHg. A decrease in OI by ≥ 20% was defined as a significant improvement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean arterial blood pressure (MABP)</measure>
    <time_frame>At baseline to 2, 6, 12, and 24 hours following study drug administration.</time_frame>
    <description>Changes in mean arterial blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum magnesium level</measure>
    <time_frame>At baseline to 12 hours after study drug adminstration</time_frame>
    <description>Changes in serum magnesium level</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Persistent Fetal Circulation</condition>
  <condition>Persistent Pulmonary Hypertension of the Newborn</condition>
  <condition>PPHN</condition>
  <arm_group>
    <arm_group_label>NebMag</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neonates with PPHN receiving nebulized magnesium sulfate and intravenous placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IVMag</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Neonates with PPHN receiving intravenous magnesium sulfate and nebulized placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nebulized Magnesium Sulfate</intervention_name>
    <description>Nebulized magnesium sulfate (isotonic solution) 256 mg every 15 minutes</description>
    <arm_group_label>NebMag</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous Magnesium Sulfate</intervention_name>
    <description>Intravenous magnesium sulfate 200 mg/kg over 30 minutes, followed by a continuous infusion at a rate of 50 mg/kg/hour</description>
    <arm_group_label>IVMag</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Newborns with PPHN fulfilling the following:

          1. born at ≥ 37 weeks gestational age.

          2. birth weight between 2.5 and 4 kg.

          3. post-natal age between 6 and 72 hours.

          4. connected to mechanical ventilation with an oxygenation index (OI) &gt; 30 on two
             occasions at least 15 minutes apart.

          5. documented PPHN confirmed by echocardiography.

        Exclusion Criteria:

          1. failure to obtain informed consent.

          2. infants of mothers who received magnesium sulfate within 48 hours before labor.

          3. congenital heart diseases (other than PDA and foramen ovale).

          4. major congenital anomalies (including congenital diaphragmatic hernia and lung
             hypoplasia).

          5. prior need for cardiopulmonary resuscitation.

          6. mean arterial blood pressure (MABP) &lt; 35 mmHg despite therapy with volume infusions
             and dopamine infusion up to 20 μg/kg/min.

          7. impaired kidney function.

          8. prior administration of pulmonary vasodilators, surfactant, or inotropes other than
             dopamine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>72 Hours</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elsayed Abdelkreem, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of Medicine, Sohag University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Neonatal Intensive Care Unit, Sohag University Hospital</name>
      <address>
        <city>Sohag</city>
        <zip>82524</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 29, 2020</study_first_submitted>
  <study_first_submitted_qc>March 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 31, 2020</study_first_posted>
  <last_update_submitted>March 29, 2020</last_update_submitted>
  <last_update_submitted_qc>March 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sohag University</investigator_affiliation>
    <investigator_full_name>Elsayed Abdelkreem</investigator_full_name>
    <investigator_title>Lecturer of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>neonate</keyword>
  <keyword>persistent fetal circulation</keyword>
  <keyword>persistent pulmonary hypertension of the newborn</keyword>
  <keyword>PPHN</keyword>
  <keyword>Magnesium Sulfate</keyword>
  <keyword>Nebulizer</keyword>
  <keyword>hypoxia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Persistent Fetal Circulation Syndrome</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Magnesium Sulfate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

